CN114040753A - 超粒子制剂 - Google Patents

超粒子制剂 Download PDF

Info

Publication number
CN114040753A
CN114040753A CN202080028418.7A CN202080028418A CN114040753A CN 114040753 A CN114040753 A CN 114040753A CN 202080028418 A CN202080028418 A CN 202080028418A CN 114040753 A CN114040753 A CN 114040753A
Authority
CN
China
Prior art keywords
super
sps
composition
another example
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080028418.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·维斯
马玉添
F·卡鲁索
M·布乔恩马尔姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Bionics Institute
Original Assignee
University of Melbourne
Bionics Institute of Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019900910A external-priority patent/AU2019900910A0/en
Application filed by University of Melbourne, Bionics Institute of Australia filed Critical University of Melbourne
Publication of CN114040753A publication Critical patent/CN114040753A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526—Head electrodes
    • A61N1/0541—Cochlear electrodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36036—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of the outer, middle or inner ear
    • A61N1/36038—Cochlear stimulation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080028418.7A 2019-03-19 2020-03-19 超粒子制剂 Pending CN114040753A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019900910 2019-03-19
AU2019900910A AU2019900910A0 (en) 2019-03-19 Improved supraparticles II
PCT/AU2020/050260 WO2020186304A1 (en) 2019-03-19 2020-03-19 Supraparticle formulations

Publications (1)

Publication Number Publication Date
CN114040753A true CN114040753A (zh) 2022-02-11

Family

ID=72518918

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080028418.7A Pending CN114040753A (zh) 2019-03-19 2020-03-19 超粒子制剂

Country Status (6)

Country Link
US (1) US12551450B2 (https=)
EP (1) EP3941442A4 (https=)
JP (1) JP2022525945A (https=)
CN (1) CN114040753A (https=)
AU (1) AU2020242921B2 (https=)
WO (1) WO2020186304A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117065055A (zh) * 2022-05-24 2023-11-17 天津医科大学第二医院 一种核壳型纳米酶探针及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631011A (en) * 1991-06-17 1997-05-20 Wadstroem; Jonas Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
JPH10236984A (ja) * 1997-02-28 1998-09-08 Hoechst Marion Roussel Kk 徐放性局所送達製剤
CN1627924A (zh) * 2002-02-06 2005-06-15 奥勃斯医学技术股份有限公司 包覆有可促进内皮细胞的黏附和分化的包衣医疗装置
CN101168062A (zh) * 2006-10-23 2008-04-30 中国科学院理化技术研究所 双壳层药物缓控释载体材料及其制备方法和用途
CN103467755A (zh) * 2013-09-18 2013-12-25 薛巍 一种药物缓释水凝胶及其制备方法与用途
CN107375196A (zh) * 2017-07-26 2017-11-24 暨南大学 一种含儿茶酚基天然多糖复合水凝胶载体及其制备方法
CN107865822A (zh) * 2017-08-25 2018-04-03 中南民族大学 一种掺入纳米介孔二氧化硅的水凝胶药物缓释载体材料的制备方法和应用
CN108384031A (zh) * 2017-06-27 2018-08-10 中南民族大学 一种缓释水凝胶载体材料的制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468498A (en) 1980-06-12 1984-08-28 Rohm And Haas Company Sequential heteropolymer dispersion and a particulate materal obtainable therefrom, useful in coating compositions as a thickening and/or opacifying agent
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US5157084A (en) 1990-10-12 1992-10-20 The Dow Chemical Company Process of making hollow polymer latex particles
US5521253A (en) 1990-10-12 1996-05-28 The Dow Chemical Company Hollow polymer latex particles
KR960016882A (ko) * 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
WO2006037160A1 (en) 2004-10-05 2006-04-13 The University Of Melbourne Porous polyelectrolyte materials
BRPI0806803A2 (pt) * 2007-01-19 2011-09-13 Iams Company composição e método de ingrediente sensìvel estabilizado
WO2018013928A1 (en) * 2016-07-14 2018-01-18 University Hospitals Cleveland Medical Center Compositions and methods for collagen-based sutures and antibacterial coatings
AU2018337076B2 (en) * 2017-09-20 2024-09-26 The Bionics Institute Of Australia Method of treatment

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631011A (en) * 1991-06-17 1997-05-20 Wadstroem; Jonas Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
JPH10236984A (ja) * 1997-02-28 1998-09-08 Hoechst Marion Roussel Kk 徐放性局所送達製剤
CN1627924A (zh) * 2002-02-06 2005-06-15 奥勃斯医学技术股份有限公司 包覆有可促进内皮细胞的黏附和分化的包衣医疗装置
CN101168062A (zh) * 2006-10-23 2008-04-30 中国科学院理化技术研究所 双壳层药物缓控释载体材料及其制备方法和用途
CN103467755A (zh) * 2013-09-18 2013-12-25 薛巍 一种药物缓释水凝胶及其制备方法与用途
CN108384031A (zh) * 2017-06-27 2018-08-10 中南民族大学 一种缓释水凝胶载体材料的制备方法和应用
CN107375196A (zh) * 2017-07-26 2017-11-24 暨南大学 一种含儿茶酚基天然多糖复合水凝胶载体及其制备方法
CN107865822A (zh) * 2017-08-25 2018-04-03 中南民族大学 一种掺入纳米介孔二氧化硅的水凝胶药物缓释载体材料的制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YUTIAN MA等: ""Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery"，Yutian Ma等，《ACS Appl. Mater. Interfaces》，第10期，第31019-31031页", 《ACS APPL. MATER. INTERFACES》 *
顾其胜: "《海藻酸盐基生物医用材料与临床医学》", 30 April 2015, 上海科学技术出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117065055A (zh) * 2022-05-24 2023-11-17 天津医科大学第二医院 一种核壳型纳米酶探针及其制备方法和应用
CN117065055B (zh) * 2022-05-24 2025-08-29 天津医科大学第二医院 一种核壳型纳米酶探针及其制备方法和应用

Also Published As

Publication number Publication date
EP3941442A4 (en) 2022-12-21
US12551450B2 (en) 2026-02-17
US20220168228A1 (en) 2022-06-02
AU2020242921B2 (en) 2025-04-03
JP2022525945A (ja) 2022-05-20
WO2020186304A1 (en) 2020-09-24
EP3941442A1 (en) 2022-01-26
AU2020242921A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
Abasalizadeh et al. Alginate-based hydrogels as drug delivery vehicles in cancer treatment and their applications in wound dressing and 3D bioprinting
US20250205308A1 (en) Supraparticles
Jia et al. Chemical and structural engineering of gelatin-based delivery systems for therapeutic applications: a review
US20130196915A1 (en) Affinity hydrogels for controlled protein release
Shultz et al. Hydrogel-based local drug delivery strategies for spinal cord repair
Shadjou et al. Silica‐based mesoporous nanobiomaterials as promoter of bone regeneration process
Mi et al. Injectable nanoparticles/hydrogels composite as sustained release system with stromal cell-derived factor-1α for calvarial bone regeneration
US11213490B2 (en) Encapsulation-free controlled protein release system
CN107660220A (zh) 超支化聚合物和多聚复合物及包含其的dna或rna递送系统
Du et al. Nanocomposites for the delivery of bioactive molecules in tissue repair: vital structural features, application mechanisms, updated progress and future perspectives
Mondalek et al. Enhanced angiogenesis of modified porcine small intestinal submucosa with hyaluronic acid‐poly (lactide‐co‐glycolide) nanoparticles: From fabrication to preclinical validation
Ansari et al. Recent advances in nanostructured delivery systems for vancomycin
Li et al. An injectable, self-healing and degradable hydrogel scaffold as a functional biocompatible material for tissue engineering applications
Shin et al. Extracellular matrix-inspired BMP-2-delivering biodegradable fibrous particles for bone tissue engineering
Silva et al. Composites based on chitosan and inorganic materials for biomedical applications
Negron et al. Non-adhesive and highly stable biodegradable nanoparticles that provide widespread and safe transgene expression in orthotopic brain tumors
AU2020242921B2 (en) Supraparticle formulations
Lu Polymer-Ceramic Hybrid Nanoparticles: Promising Strategies for Controlled Drug Release
KR101629563B1 (ko) 성장인자를 함유한 생분해용 폴리머-쉘화된 메소포러스 나노구가 삽입된 치료용 폼 스캐폴드
Minden-Birkenmaier et al. Electrospun systems for drug delivery
CN117138058A (zh) 用于修复骨缺损的脂质体、水凝胶及制备方法与应用
Martins et al. Delivery Systems Made of Natural‐Origin Polymers for Tissue Engineering and Regenerative Medicine Applications
Hosseinpour et al. Nanobiomaterials in Craniofacial Bone Regeneration
Briggs et al. Growth factor delivery from electrospun materials
Carrêlo Smart Hydrogel-Based Injectable Systems for Breast Cancer Theranostics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination